Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment (BINDeR-TX)

Jerry Cochran

Status: Completed

Conditions: Opioid Abuse

Treatments: Behavioral: Implementation of the BINDeR-Tx service model

Study type: Observational

Funder types: Other

Identifiers

NCT06087991

158724

Details and patient eligibility

About

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.

Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

Full description

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.

The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.

This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For qualitative interviews with providers, administrators, stakeholders:

• Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.

For the quantitative surveys:

• Must be a Castleview Hospital patient who receives the BINDeR-Tx model.

Exclusion criteria

For qualitative interviews with providers, administrators, stakeholders:

• Not familiar with the BINDeR-Tx model
• No interaction with the BINDeR-Tx model

For the quantitative surveys:

• Unable to speak and read English
• Subject is unable to provide contact information

Trial design

65 participants in 2 patient groups

Quantitative Interviews

Description:

Any Castleview patient who participates in this model will be emailed both the Patient Satisfaction Questionnaire Short Form (PSQ 18) and the Government Performance and Results Act surveys after hospital discharge, six months, and at discharge for buprenorphine.

Treatment:

Behavioral: Implementation of the BINDeR-Tx service model

Qualitative Interviews

Description:

Qualitative interviews among providers, stakeholders and community members associated with Castleview Hospital will be conducted after the model has been deployed. The qualitative interviews will come from The Consolidated Framework for Implementation Research (CFIR) which is a validated tool that was developed that was developed to evaluate implementation studies.

Treatment:

Behavioral: Implementation of the BINDeR-Tx service model